Pharmaceutical Executive Daily: New Research on Ozempic
Today's Pharmaceutical Executive Daily covers key news in the pharmaceutical and life sciences industry.
- FDA approval of Bayer's Lynkuet for menopausal hot flashes.
- New research suggesting Ozempic may reduce biological age.
- Novartis' $12 billion merger agreement to acquire Avidity Biosciences.
The FDA approved Bayer's Lynkuet, a dual neurokinin 1 and 3 receptor antagonist, for treating moderate to severe vasomotor symptoms associated with menopause.
Lynkuet provides a non-hormonal option, offering an alternative for patients seeking relief without estrogen exposure, based on Phase III OASIS trial data.
No direct quote available in the given text.
Author's summary: New research on Ozempic and FDA approvals shape the industry.
More News
- Arcade takes centre stage at DigiCon 2025 as personalisation and AI set the agenda for Asia’s creative future
- Making Southeast Asia’s AI numbers stack up
- Environment and Sustainable Development 5 Minute F... | Clayton Utz
- Ned Nwoko pins South-East unrest to marginalisation
- Nigeria: Christian Genocide and the Dangers of Mischaracterisation
- Rethinking Sharia Law in Britain
- Alleged Charlie Kirk assassin allowed to wear street clothes at trial
- Why the Informal Sector Is Not a Tax Goldmine - Institute of Development Studies
- Yes, There Are AI Stocks in Canada: Here's How They Stack Up
- Most purchases come from consumers already ‘primed’ to buy